Stock Screener App

Frei -

Installieren

29.27

7.33% 2.00

after-market

Handel nachbörslich: 29.35 0.08 +0.27%

Alumis Inc (ALMS)

Überblick Nachrichten Preisverlauf Forum Prognose

Alumis Inc Aktie (ALMS) Neueste Nachrichten

[144] ALUMIS INC. SEC Filing - Stock Titan

Price to sales forward of Alumis Inc. – NASDAQ:ALMS - TradingView

Form 4 Alumis Inc For: 2 July By Investing.com - Investing.com Canada

Alumis (ALMS) director Lynn Tetrault receives RSU and stock option awards - Stock Titan

Director at ALUMIS (NASDAQ: ALMS) receives RSU and option grants - Stock Titan

[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan

Alumis (ALMS) director awarded new RSUs and stock options - Stock Titan

Alumis (ALMS) director Akkaraju receives RSUs, options and reports fund stakes - Stock Titan

Form 13D/A Alumis Inc. For: 2 July By Investing.com - Investing.com Nigeria

Alumis (ALMS) major holder keeps 15.1M-share stake as ownership hits 12.3% - Stock Titan

[8-K] ALUMIS INC. Reports Material Event - Stock Titan

Stifel and Guggenheim Stay Bullish on Alumis (ALMS) - Insider Monkey

Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS - TradingView

Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $51 - Moomoo

Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS - TradingView

Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark - marketscreener.com

ALMS Forecast — Price Target — Prediction for 2027 - TradingView

Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Alumis Unveils Breakthrough TYK2 Inhibitors: Leading Clinical Results in Psoriasis and Lupus, $180B+ Market Opportunity by 2030 318 – Minichart - Minichart

Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 2000 Value Benchmark - marketscreener.com

Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing - TradingView

Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation - Stock Titan

Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark - marketscreener.com

Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed - simplywall.st

Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 3000E Value Benchmark - marketscreener.com

Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55 - Moomoo

Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon - Seeking Alpha

Alumis Inc. Actuals & Estimates (BOATS:ALMS) - TradingView

Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC - Moomoo

Alumis Inc. (ALMS) Sees Modest Gain as Stock Consolidates Near ResistanceETF Liquidity - dars.gov.et

Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Alumis Inc (ALMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Alumis Inc (ALMS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Alumis Inc (ALMS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Alumis Inc (ALMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Alumis Inc (ALMS) Institutional Confidence - TradingKey

ALMS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesROIC Trend Report - dars.gov.et

Alumis Inc (ALMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Alumis Inc (ALMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks

ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com

Alumis | ARS: Annual Report to Security Holders - Moomoo

Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06 - GuruFocus

ALUMIS INC (ALMS) Stock Chart - ChartMill

Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²

Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks

ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com

Alumis | SCHEDULE 13D/A: Others - Moomoo

ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus

Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks

ALMS Q1 2026 Earnings: EPS Surprises to the Upside Amid Pre-Revenue Clinical StagePre-Earnings Drift - newsline.com

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment - Kavout

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - Insider Monkey

ALMS Q1 2026 Earnings: EPS Beat Partially Offsets Investor ConcernsProfit Cycle Analysis - The Legal Advocate

Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares - Stock Titan

ALMSAlumis Inc Stock Price and Quote - Finviz

10 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey

TOWERVIEW LLC's Alumis Inc(ALMS) Holding History - GuruFocus

Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Mirrors Operational Discipline, Pre-Revenue Stage PersistsEPS Guidance Update - The Legal Advocate

Alumis Inc. (ALMS) Edges Lower, Consolidating Above Key Support LevelWyckoff Distribution - newsline.com

How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st

Alumis | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo

Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga

INSM

$112.84

1.17%

RPRX

$57.80

1.55%

ROIV

$36.31

2.60%

MRNA

$79.77

2.48%

ONC

$308.96

0.16%

RVMD

$190.46

0.25%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters